Day One Biopharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€160.99M - Cost of goods sold
€9.63M - Gross profit
€151.37M - SG&A expenses
€100.39M - R&D expenses
€146.85M - EBITDA
-€94.45M - D&A
€2.25M - EBIT
-€95.87M - Interest expenses
€0.00 - EBT
-€76.71M - Tax expenses
€4.80M - Net income
-€81.51M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€36.51M - Changes in working capital
-€51.69M - Operating cash flow
-€54.10M - Capex
€49.30M - Other investing cash flow
-€64.84M - Net investing cash flow
-€294.83M - Total cash dividends paid
€0.00 - Issuance of common stock
€154.46M - Debt repayment
€0.00 - Other financing cash flow
€20.39M - Net financing cash flow
€173.91M - Foreign exchange effects
€0.00 - Net change in cash
-€175.03M - Cash at end of period
€30.56M - Free cash flow
-€4.80M
Balance sheet
- Cash and cash equivalents
€30.56M - Cash and short-term investments
€388.76M - Total receivables
€16.88M - Inventory
€5.61M - Other current assets
€12.97M - Total current assets
€424.22M - Property, plant & equipment
€4.13M - Goodwill
€0.00 - Intangible assets
€16.83M - Long-term investments
€0.00 - Other non-current assets
€157.01K - Total non-current assets
€21.11M - Total assets
€445.33M - Accounts payable
€4.37M - Short-term debt
€262.55K - Other current liabilities
€37.73M - Total current liabilities
€43.95M - Long-term debt
€4.89M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€652.94K - Total non-current liabilities
€5.99M - Total liabilities
€49.94M - Common stock
€8.58K - Retained earnings
-€532.30M - Other equity
-€78.94K - Total equity
€395.40M - Total liabilities and shareholders' equity
€445.33M
Company information
- Market capitalization
€559.38M - Employees
181 - Enterprise Value
€653.75M
Company ratios
- Gross margin
-
94.0% Much better than peer group: -12,252.1% - EBITDA margin
-
-58.7% Much better than peer group: -1,737,009.4% - EBIT margin
-
-59.5% Much better than peer group: -1,749,564.1% - EBT margin
-
-47.6% Much better than peer group: -1,745,668.4% - Net margin
-
-50.6% Much better than peer group: -1,674,456.5% - ROE
-
-20.6% Much better than peer group: -51.3% - ROA
-
-18.3% Much better than peer group: -49.6% - Asset turnover
-
36.2% Much better than peer group: 3.5% - FCF margin
-
-64.2% Much better than peer group: -1,370,143.1% - FCF yield
-18.5% - Efficiency ratio
158.7% - Net sales per employee
-
€889.47K - Net income per employee
-
-€450.31K